Metabolomic-Driven elucidation of serum disturbances associated with Alzheimer’s disease and mild cognitive impairment

Current Alzheimer Research

Volumn 13, Issue 6, 2016, Pages 641-653

  González Domínguez, Raúl ^a   Rupérez, Francisco Javier ^b   García Barrera, Tamara ^a   Barbasd, Coral ^b   Gómez Ariza, José Luis ^a  

^a UNIVERSITY OF HUELVA   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

Alzheimer s disease; Disease progression; Membrane breakdown; Metabolomics; Mild cognitive impairment; Pathological mechanisms

Indexed keywords

ACYLCARNITINE; ACYLGLYCEROL LIPASE; ARAQUIDONIC ACID; BIOLOGICAL MARKER; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CHOLINE; DOCOSAHEXAENOIC ACID; ETHANOLAMINE; GLUTAMINE; LACTOSYLCERAMIDE; MONOACYLGLYCEROL; OLEAMIDE; PHENYLACETYLGLUTAMINE; PHOSPHOETHANOLAMINE; PHOSPHOLIPID; PHOSPHORYLCHOLINE; PLASMALOGEN; SPHINGOLIPID; SPHINGOSINE; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ACYLATION; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; BRAIN METABOLISM; CONTROLLED STUDY; DEACYLATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FEMALE; HUMAN; LIPID DEGRADATION; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MILD COGNITIVE IMPAIRMENT; MITOCHONDRIAL RESPIRATION; NERVE CELL MEMBRANE; OXIDATIVE STRESS; PRIORITY JOURNAL; SPHINGOLIPID METABOLISM; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPREGULATION; BLOOD; BLOOD ANALYSIS; COGNITIVE DEFECT; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOME;

AGED; ALZHEIMER DISEASE; BIOMARKERS; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COGNITIVE DYSFUNCTION; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METABOLOME;

EID: 84966417230     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205013666160129095138     Document Type: Article

References (55)

1. McKahnn G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer´s disease. Neurology 34: 939-44 (1984).
2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7: 263-9 (2011).
3. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 256: 183-94 (2004).
4. Dean RA, Shaw LM. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment. Clin Chem 56: 17-9 (2000).
5. Reiman ER, Jagust WJ. Brain imaging in the study of Alzheimer’s disease. NeuroImage 61: 505-16 (2012).
6. Tukiainen T, Tynkkynen T, Makinen VP, Jylanki P, Kangas A, Hokkanen J, et al. A multi-metabolite analysis of serum by 1H NMR spectroscopy: Early systemic signs of Alzheimer’s disease. Biochem Biophys Res Commun 375: 356-61 (2008).
7. Zheng J, Dixon RA, Li L. Development of isotope labeling LC−MS for human salivary metabolomics and application to profiling metabolome changes associated with mild cognitive impairment. Anal Chem 84: 10802-11 (2012).
8. Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C. A proposed metabolic strategy for monitoring disease progression in Alzheimer’s disease. Electrophoresis 30: 1235-9 (2009).
9. Oresic M, Hyotylainen T, Herukka SK, Sysi-Aho M, Mattila I, Seppanan-Laakso T, et al. Metabolome in progression to Alzheimer’s disease. Transl Psychiatry 1: e57 (2011).
10. Armirotti A, Basit A, Realini N, Caltagirone C, Bossu P, Spalletta G, et al. Sample preparation and orthogonal chromatography for broad polarity range plasma metabolomics: application to human subjects with neurodegenerative dementia. Anal Biochem 455: 48-54 (2014).
11. Wang G, Zhou Y, Huang FJ, Tang HD, Xu XH, Liu JJ, et al. Plasma metabolite profiles of Alzheimer’s disease and mild cognitive impairment. J Proteome Res 13: 2649-58 (2014).
12. Gonzalez-Dominguez R, Garcia A, Garcia-Barrera T, Barbas C, Gomez-Ariza JL. Metabolomic profiling of serum in the progression of Alzheimer’s disease by capillary electrophoresis-mass spectrometry. Electrophoresis 35: 3321-30 (2014).
13. Ibanez C, Simo C, Martin-Alvarez PJ, Kivipelto M, Winblad B, Cedazo-Minguez A, et al. Toward a predictive model of Alzheimer’s disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal Chem 84: 8532-40 (2012).
14. Ibanez C, Simo C, Barupal DK, Fiehn O, Kivipelto M, Cedazo-Minguez A, et al. A new metabolomic workflow for early detection of Alzheimer’s disease. J Chromatogr A 1302: 65-71 (2013).
15. Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, et al. Alterations in metabolic pathways and networks in Alzheimer’s disease. Transl Psychiatry 3: e244 (2013).
16. Trushina E, Dutta T, Persson XMT, Mielke MM, Petersen RC. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer’s disease using metabolomics. Plos One 8: e63644 (2013).
17. Wilson ID, Nicholson JK, Castro-Perez J, Granger JH, Johnson KA, Smith BW, et al. High resolution “ultra performance” liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J Proteome Res 4: 591-8 (2005).
18. Bujak R, Garcia-Alvarez A, Ruperez FJ, Nuno-Ayala M, Garcia A, Ruiz-Cabello J, et al. Metabolomics reveals metabolite changes in acute pulmonary embolism. J Proteome Res 13: 805-16 (2014).
19. Godzien J, Garcia-Martinez D, Martinez-Alcazar P, Ruperez FJ, Barbas C. Effect of a nutraceutical treatment on diabetic rats with targeted and CE-MS non-targeted approaches. Metabolomics 9: 188-202 (2013).
20. van den Berg RA, Hoefsloot HCJ, Westerhuis JA, Smilde AK, van der Werf MJ. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genom 7: 142 (2006).
21. Gonzalez-Dominguez R, Garcia-Barrera T, Gomez-Ariza JL. Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer’s disease, J Proteomics 104: 37-47 (2014).
22. Haynes CA, Allegood JC, Park H, Sullards MC. Sphingolipidomics: Methods for the comprehensive analysis of sphingolipids. J Chromatogr B 877: 2696-708 (2009).
23. Vernez L, Hopfgartner G, Wenk M, Krahenbuhl S. Determination of carnitine and acylcarnitines in urine by high-performance liquid chromatography-electrospray ionization ion trap tandem mass spectrometry. J Chromatogr A 984: 203-13 (2003).
24. Masson P, Spagou K, Nicholson JK, Want EJ. Technical and biological variation in UPLC-MS-based untargeted metabolic profiling of liver extracts: application in an experimental toxicity study on galactosamine. Anal Chem 83: 1116-23 (2011).
25. Gonzalez-Dominguez R, Garcia-Barrera T, Vitorica J, Gomez-Ariza JL. Application of metabolomics based on direct mass spectrometry analysis for the elucidation of altered metabolic pathways in serum from the APP/PS1 transgenic model of Alzheimer’s disease. J Pharm Biomed Anal 107: 378-85 (2015).
26. Gonzalez-Dominguez R, Garcia-Barrera T, Vitorica J, Gomez-Ariza JL. Deciphering metabolic abnormalities associated with Alzheimer’s disease in serum from the APP/PS1 mouse model using integrated metabolomics approaches. Biochimie 110: 119-28 (2015).
27. Gonzalez-Dominguez R, Garcia-Barrera T, Vitorica J, Gomez-Ariza JL. Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer’s disease by direct infusion mass spectrometry. J Pharm Biomed Anal 102: 425-35 (2015).
28. Gonzalez-Dominguez R, Garcia-Barrera T, Vitorica J, Gomez-Ariza JL. Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer’s disease. Biochim Biophys Acta 1842: 2395-402 (2014).
29. Morris JK, Honea RA, Vidoni ED, Swerdlow RH, Burns JM. Is Alzheimer’s disease a systemic disease? Biochim Biophys Acta 1842: 1340-9 (2014).
30. Farooqui AA, Ong WY, Horrocks LA. Biochemical aspects of neurodegeneration in human brain: involvement of neural membrane phospholipids and phospholipases A2. Neurochem Res 29: 1961-77 (2004).
31. Gonzalez-Dominguez R, Garcia-Barrera T, Gomez-Ariza JL. Metabolomic study of lipids in serum for biomarker discovery in Alzheimer’s disease using direct infusion mass spectrometry. J Pharm Biomed Anal 98: 321-6 (2014).
32. Cunnane SC, Schneider JA, Tangney C, Tremblay-Mercier J, Fortier M, Bennett DA, et al. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 29: 691-7 (2012).
33. Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer’s disease. Lipids 26: 421-5 (1991).
34. Gonzalez-Dominguez R, Garcia-Barrera T, Gomez-Ariza JL. Using direct infusion mass spectrometry forserum metabolomics in Alzheimer’s disease. Anal Bioanal Chem 406: 7137-48 (2014).
35. Li N, Liu W, Li W, Li S, Chen X, Bi K, et al. Plasma metabolic profiling of Alzheimer’s disease by liquid chromatography/mass spectrometry. Clin Biochem 43: 992-7 (2010).
36. Ryan SD, Whitehead SN, Swayne LA, Moffat TC, Hou W, Ethier M, et al. Amyloid-beta42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. Proc Natl Acad Sci USA 106: 20936-41 (2009).
37. Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: A shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease? Neurochem Res 32: 845-56 (2007).
38. He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol Aging 31: 398-408 (2010).
39. Han X, Holtzman D, McKeel DW, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: Potential role in disease pathogenesis. J Neurochem 82: 809-18 (2002).
40. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, et al. Metabolomics in early Alzheimer’s disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 6: e21643 (2011).
41. Gonzalez-Dominguez R, Garcia-Barrera T, Gomez-Ariza JL. Application of a novel metabolomic approach based on atmospheric pressure photoionization mass spectrometry using flow injection analysis for the study of Alzheimer’s disease. Talanta 131: 480-9 (2015).
42. Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 287: 2678-88 (2012).
43. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci USA 101: 2070-5 (2004).
44. Kosicek M, Zetterberg H, Andreasen N, Peter-Katalinic J, Hecimovic S. Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer’s disease. Neurosci Lett 516: 302-5 (2012).
45. Mielke MM, Bandaru VVR, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC. Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 31: 17-24 (2010).
46. Takasugi N, Sasaki T, Suzuki K, Osawa S, Isshiki H, Hori Y, et al. BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J Neurosci 31: 6850-7 (2011).
47. Ariga T, McDonald MP, Yu RK. Role of ganglioside metabolism in the pathogenesis of Alzheimer’s disease-a review. J Lipid Res 49: 1157-75 (2008).
48. Mielke MM, Bandaru VV, Haughey NJ, Xia J, Fried LP, Yasar S, et al. Serum ceramides increase the risk of Alzheimer disease: the Women’s Health and Aging Study II. Neurology 79: 633-41 (2012).
49. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J Neurosci 23: 11136-41 (2003).
50. Mulder J, Zilberter M, Pasquare SJ, Alpar A, Schulte G, Ferreira SG, et al. Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease. Brain 134: 1041-60 (2011).
51. Sigauke E, Rakheja D, Kitson K, Bennett MJ. Carnitine palmitoyltransferase II deficiency: A clinical, biochemical, and molecular review. Lab Invest 83: 1543-54 (2003).
52. Maruszak A, Żekanowski C. Mitochondrial dysfunction and Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 35: 320-30 (2011).
53. Ferreira IL, Resende R, Ferreiro E, Rego AC, Pereira CF. Multiple defects in energy metabolism in Alzheimer’s disease. Curr Drug Targets 11: 1193-206 (2010).
54. Weill-Engerer S, David JP, Sazdovitch V, Liere P, Eychenne B, Pianos A, et al. Neurosteroid quantification in human brain regions: comparison between Alzheimer’s and non-demented patients. J Clin Endocrinol Metab 87: 5138-43 (2002).
55. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol 67: 259-79 (2002).